|
|
|
|
 |
|
|
       |
|
Our focus has been on the research and commercial development of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neuro-inflammatory disorders. We are not currently advancing the development of our products and are focused on exploring strategic options that may include a sale of the Company, a merger, an acquisition by us, or other strategic alternative. |
Latest News
April 24, 2009
April 13, 2009
|
|
|
| © Vasogen Inc. 2009. Legal Notice | Privacy Policy |  Contact Us  Search  Site Map  Printable Page |
Leadership
